Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats

被引:54
作者
Arimori, K
Kuroki, N
Hidaka, M
Iwakiri, T
Yamasaki, K
Okumura, M
Ono, H
Takamura, N
Kikuchi, M
Nakano, M
机构
[1] Miyazaki Med Coll, Dept Pharm, Kiyotake, Miyazaki 8891692, Japan
[2] Kumamoto Univ Hosp, Dept Pharm, Kumamoto 8608556, Japan
[3] Daiichi Pharmaceut Co Ltd, PMS & Appl Clin Dev Dept, Chuo Ku, Tokyo 1048369, Japan
关键词
irinotecan; cyclosporin A; intestinal exsorption; biliary excretion; P-glycoprotein;
D O I
10.1023/A:1023847521767
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this work was to investigate the role of the hepatic and intestinal P-glycoprotein (P-gp) and canalicular multispecific organic anion transporter / multidrug resistance-associated protein 2 (cMOAT/MRP2) on both biliary excretion and intestinal exsorption of irinotecan hydrochloride (CPT-11) and its metabolite, SN-38, in the lactone and carboxylate forms. Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2. Methods. The transcellular transport of CPT-11 and SN-38 was examined by using LLC-PK1 derivative cell lines transfected with murine mdr1a both in the absence or in the presence of CsA. The excretions of the compounds through the biliary and intestinal membrane routes were investigated by in situ perfusion technique. Results. Basolateral-to-apical transport of CPT-11 lactone in L-mdr1a cells was significantly decreased by CsA ( 10 muM). The transcellular transport of SN-38 lactone showed similar behaviors as those of CPT-11 lactone. The biliary excretion and the intestinal exsorption of both forms of CPT-11 and SN-38 were significantly inhibited when the drug was co-administered with CsA. Conclusions. The transports of CPT-11 and SN-38 via the biliary route seem to be essentially related with cMOAT/MRP2, whereas those of both compounds via the intestinal membrane seem to be related with P-gp.
引用
收藏
页码:910 / 917
页数:8
相关论文
共 25 条
[1]  
AKIMOTO K, 1994, CHEM PHARM BULL, V42, P2135, DOI 10.1248/cpb.42.2135
[2]   Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents [J].
Arimori, K ;
Kuroki, N ;
Kumamoto, A ;
Tanoue, N ;
Nakano, M ;
Kumazawa, E ;
Tohgo, A ;
Kikuchi, M .
PHARMACEUTICAL RESEARCH, 2001, 18 (06) :814-822
[3]   Drug exsorption from blood into the gastrointestinal tract [J].
Arimori, K ;
Nakano, M .
PHARMACEUTICAL RESEARCH, 1998, 15 (03) :371-376
[4]  
ARIMORI K, 1985, J PHARMACOBIO-DYNAM, V8, P324
[5]  
Chu XY, 1997, CANCER RES, V57, P1934
[6]  
Chu XY, 1997, J PHARMACOL EXP THER, V281, P304
[7]  
Chu XY, 1998, CANCER RES, V58, P5137
[8]  
Chu XY, 1999, DRUG METAB DISPOS, V27, P440
[9]  
Chu XY, 1999, J PHARMACOL EXP THER, V288, P735
[10]   Regulation of expression of the multidrug resistance associated protein 2 (MRP2) and its role in drug disposition [J].
Gerk, PM ;
Vore, M .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (02) :407-415